56 results about "Clostridium difficile toxin B" patented technology

A low odor, liquid disinfectant composition comprising multiple components, which, upon mixing, provide an aqueous solution comprising low levels of peracetic acid for use in decontaminating articles and surfaces contaminated with bacteria, viruses, fungi and other biological contaminants such as spores, including, but not limited to, Clostridium difficile (C.diff). The disinfectant composition is prepared just prior to use by combining two or more separately packaged components.

A provided multiple fluorescence PCR detection kit for clostridium difficile toxin genes mainly comprises specific primers, probes and a PCR reaction reagent, and the specific primers and the probes respectively consist of specific primers and probes of clostridium difficile toxin A (tcdA), toxin B (tcdB), binary toxin A (cdtA) and binary toxinB (cdtB). The beneficial effects of the invention comprise: the fast, sensitive and specific multiple fluorescence PCR detection kit and a detection method are provided for the clostridium difficile toxin genes, and a foundation is provided for distinguishing between toxigenic strains and avirulent strains of clostridium difficile, and early diagnosis on infection of clostridium difficile.

The invention discloses a composition, kit and method for detecting high-virulence bacterial strains and/or toxin type of clostridium difficile. The composition and kit comprise primers, probes and standard substances, wherein the nucleotide sequence of the primers is as shown in SEQ ID NO. 1-47; the high-virulence bacterial strains and/or toxin type of clostridium difficile can be detected through fluorogenic quantitative PCR by adopting the composition or kit. According to the invention, the sensitivity and specificity are high; the toxin type and virulence of clostridium difficile can be accurately judged through detecting tcdC gene mutation or deletion and coordinating with virulence gene detection, including tcd A/B and binary virulence gene cdt A/B, of clostridium difficile.

A system and process for disinfecting rooms such as health care facility rooms with an oxygen/ozone mixture is described, which is effective to combat “superbugs” such as Clostridium difficile (C. difficile); E. coli; Pseudomonas aeruginosa; methicillin-resistant Staphylococcus aureus (MRSA); and vancomycin-resistant Enterococcus (VRE). In preferred embodiments, hydrogen peroxide is additionally used. The system and process is effective to destroy bacteria deposited on surfaces as biofilm, and, accompanied by physical agitation such as jet nozzle outlets, is effective to disinfect carpet, drapery and similar absorbent and porous surfaces.

This invention relates to prophylactic and/or therapeutic application of microorganism species that are, for example, administered orally as delayed release formulation designed to release its microbial content to the distal small intestine and/or colon in high quantities and density, which is a “normalized” approach to repopulate the colonic flora as a method of prevention and/or treatment of, for example, Clostridium difficile colitis.

In some embodiments, the present invention provides isolated nucleotide sequences that encode Clostridium difficile toxin B, wherein the isolated nucleotide sequences have been optimized for improved expression of the toxin B in a bacterial cell. Other embodiments of the present invention pertain to methods of expressing recombinant Clostridium difficile toxin B in a bacterial cell from the isolated nucleotide sequences of the present invention. In other embodiments, the present invention pertains to bacterial cells that comprise the isolated nucleotide sequences of the present invention. In further embodiments, the invention pertains to isolated peptides of recombinant Clostridium difficile toxin B that were derived from the isolated nucleotide sequences of the present invention.

A system and process for disinfecting rooms such as health care facility rooms with an oxygen/ozone mixture is described, which is effective to combat “superbugs” such as Clostridium difficile (C. difficile); E. coli; Pseudomonas aeruginosa; methicillin-resistant Staphylococcus aureus (MRSA); and vancomycin-resistant Enterococcus (VRE). In preferred embodiments, hydrogen peroxide is additionally used. The system and process is effective to destroy bacteria deposited on surfaces as biofilm, and, accompanied by physical agitation such as jet nozzle outlets, is effective to disinfect carpet, drapery and similar absorbent and porous surfaces.

The invention discloses an LAMP detection method for clostridium difficile AB toxins and a special primer and a kit thereof. The LAMP detection method disclosed by the invention comprises the following steps: designing a primer according to the specific conserved genes tcdA and tcdB of clostridium difficile; then, by taking a genomic DNA of an object to be detected as a template, carrying out LAMP amplification under the guide of the obtained primer; and synchronously and qualitatively detecting toxigenic strains of clostridium difficile in a sample to be detected through the color changes and turbidity changes of a reaction liquid. According to the invention, toxigenic strains of clostridium difficile can be detected in a fast, convenient, synchronous, high efficiency, high specificity and high sensitivity mode under isothermal conditions without using complex instruments, so that a new technical platform is provided for the detection and toxin classification of clostridium difficile, therefore, the LAMP detection method disclosed by the invention can be used for screening and detecting clostridium difficile by grassroots medical health units and various disease prevention and control centers, has a broad market prospect and great economic and social benefits, and is suitable for large-scale popularization and application.

The invention provides a fusion protein with clostridium difficile toxins A/B and an encoding gene and application of the fusion protein. The sequence of the fusion protein with the clostridium difficile toxins A/B is represented by SEQ ID NO:2, and the encoding gene is represented by SEQ ID NO:1. According to the fusion protein, a carrier fragment consisting of a clostridium difficile toxin A carboxyl terminal gene and a prokaryotic expression vector pET32b(+) which are modified through a codon and a fusion gene fragment consisting of a clostridium difficile toxin B carboxyl terminal structure and a flexible chain are obtained through PCR (polymerase chain reaction) multiplication segmentation; the obtained fusion fragment and the obtained carrier are respectively connected in an enzyme recycling manner, so that a recombined expression plasmid pET32b(+)-ToxA-ToxB can be obtained; after the recombined plasmid converts a host BL21(DE3) strain, the recombined plasmid can be subjected to induction expression by IPTG (isopropyl-beta-d-thiogalactoside) to obtain the fusion protein with the clostridium difficile toxins A/B. According to the fusion protein with the clostridium difficile toxins A/B, the fusion protein with the immunogenicity of the toxins A and B can be obtained, and the difficulty and the cost for researching and producing a CDAD (clostridium difficile associated diarrhea) vaccine can be reduced.

The invention discloses an enzyme-linked immunosorbent assay (ELISA) detection kit for clostridium difficile. The kit comprises the following components: a diluent, confining liquid, a clostridium difficile antibody coated ELISA plate, an ELISA second antibody, a positive reference substance, washing liquid, color developing liquid and stop liquid, wherein every 100ml of diluent contains 1ml of NP-40, 0.5-2ml of Triton X-100, 1g of BSA and 0.05ml of Tween20 phosphate buffer. The invention also discloses an application of the kit in clostridium difficile detection. The kit disclosed by the invention can efficiently detect clostridium difficile and has good application prospects.

A TaqMan/MGB probe PCR (polymerase chain reaction) technology can carry out bacterial genus identification on clostridium difficile in fecal genomes, simultaneously detect the carrying situation of toxin genes, and can judge whether a toxin A has deletion. A fecal specimen is not required to be purely cultured, and the strain identification and the toxin detection are completed in a reaction system. The method has the characteristics of simple operation, good repeatability, high flux detection specimens, short report time, and the like, and is applicable to the screening of pathogenesis of patients with diarrhea caused by clinically unexplained causes. The invention solves the technical problems that fecal specimens can be subjected to strain identification and strain toxin carrying situation screening simultaneously without being purely cultured, and a DNA (deoxyribonucleic acid) detection method for fecal genomes, which is high in sensibility, is provided. Because traditional anaerobic culture is uneasy to perform, and an enzyme immunoassay has methodology defects, according to the invention, the diagnosis rate of clostridium difficile associated diarrhea is significantly increased. Meanwhile, the invention also can be applied to the monitoring of drug used in the process of treating the diseases.

The invention discloses a fluorescent quantitative PCR detection kit for clostridium difficile toxin A/B by adopting a probe method, and a detection method, which can detect clostridium difficile and also can detect and quantify toxin A and B genes. The detection kit mainly comprises specific primers and probes, wherein the specific primers and the probes are composed of primer pairs for detecting clostridium difficile, primer pairs and probes for detecting clostridium difficile toxin A, as well as primer pairs and probes for detecting clostridium difficile toxin B. According to the detection kit and the detection method, the operation is simple, the report time is short, the clostridium difficile strains can be specifically, sensitively and accurately identified for the first time, and the key toxins A and B of clostridium difficile are detected and quantified. A foundation is laid for the early diagnosis for clostridium difficile infection, and the detection kit and the detection method are suitable for screening causes of diarrhea patients with unknown causes clinically.

The invention discloses a fusion protein and application thereof to treating clostridium difficile related diseases. The invention provides a composition composed of clostridium difficile A toxin C-terminal receptor binding domain TcdA, a clostridium difficile B toxin C-terminal receptor binding domain TcdB, a clostridium difficile spore antigen BclA3 and clostridium difficile adhesion molecules CD0873. Experiments prove that the composition immunizes mice and has good immunogenicity, and antiserum of the composition has good neutralization activity on toxin, and the composition can remarkably reduce colonization of clostridium difficile in intestinal tracts and can protect survival of the mice in clostridium difficile infection.

Novel, antibody-based binding agents derived from human and camelid immunoglobulins are described. These binding agents recognize and bind with specificity to Clostridium difficile toxin A and/or toxin B and in some cases exhibit toxin neutralizing activity. These binding agents can be used to treat or prevent primary and recurrent CDI. The binding agents include camelid V_HH peptide monomers, linked groups of V_HH peptide monomers, V_HH peptide monomers joined to antibody Fc domains, and V_HH peptide monomers joined to IgG antibodies.

Described are immunogenic proteins against Clostridium difficile. Also described are compositions comprising the immunogenic proteins. Further described are methods of preventing or treating a Clostridium difficile infection in a subject in need thereof.